These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3651528)

  • 21. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of the muscarinic agonist RS 86 on the cortisol system.
    Krieg JC; Bossert S; Pirke KM; von Zerssen D; Berger M
    Biol Psychiatry; 1987 May; 22(5):573-82. PubMed ID: 3580432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease.
    Knott V; Mohr E; Mahoney C; Engeland C; Ilivitsky V
    Neuropsychobiology; 2002; 45(3):156-60. PubMed ID: 11979067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS).
    Standish TI; Molloy DW; Bédard M; Layne EC; Murray EA; Strang D
    J Am Geriatr Soc; 1996 Jun; 44(6):712-6. PubMed ID: 8642166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.
    Mintzer JE; Kershaw P
    Int J Geriatr Psychiatry; 2003 Apr; 18(4):292-7. PubMed ID: 12673604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study.
    Wolkowitz OM; Kramer JH; Reus VI; Costa MM; Yaffe K; Walton P; Raskind M; Peskind E; Newhouse P; Sack D; De Souza E; Sadowsky C; Roberts E;
    Neurology; 2003 Apr; 60(7):1071-6. PubMed ID: 12682308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of mania with the cholinomimetic agent RS 86.
    Krieg JC; Berger M
    Br J Psychiatry; 1986 May; 148():613. PubMed ID: 3535973
    [No Abstract]   [Full Text] [Related]  

  • 30. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Farlow MR; Cyrus PA
    Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms.
    Marin DB; Green CR; Schmeidler J; Harvey PD; Lawlor BA; Ryan TM; Aryan M; Davis KL; Mohs RC
    J Am Geriatr Soc; 1997 Nov; 45(11):1331-8. PubMed ID: 9361658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cortisol responses to cholinergic drugs in Alzheimer's disease.
    Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
    Imbimbo BP; Verdelli G; Martelli P; Marchesini D
    Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial.
    Tajadini H; Saifadini R; Choopani R; Mehrabani M; Kamalinejad M; Haghdoost AA
    Complement Ther Med; 2015 Dec; 23(6):767-72. PubMed ID: 26645514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
    Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
    Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.